Literature DB >> 11397669

Treatment of medullary thyroid carcinoma: an update.

F Orlandi1, P Caraci, A Mussa, E Saggiorato, G Pancani, A Angeli.   

Abstract

Prognosis and treatment effectiveness of medullary thyroid carcinoma (MTC) are largely related to the tumour stage, so that early diagnosis represents an important goal for the management of patients. Recent advances in genetic testing have improved the clinical approach to the familial MTC syndromes. There is general agreement that the primary operation for MTC should obtain the complete removal of the neoplastic tissue in the neck, because any adjuvant treatment has never been proven to be effective. The management of residual/recurrent or metastatic MTC still remains controversial, although a multimodal approach to advanced disease may be of value in palliation or local control of tumour progression. The role of surgery, external radiotherapy, radionuclide therapy and medical treatment, including biological response modifiers and cytotoxic drugs, are reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397669     DOI: 10.1677/erc.0.0080135

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  12 in total

1.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

2.  Giant intracranial medullary thyroid carcinoma metastasis presenting as apoplexy.

Authors:  Matthew Bobinski; Claudia M Greco; Rudolph J Schrot
Journal:  Skull Base       Date:  2009-09

Review 3.  Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Authors:  Matthias Drosten; Brigitte M Pützer
Journal:  J Mol Med (Berl)       Date:  2003-06-14       Impact factor: 4.599

4.  The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Authors:  Mohsen Beheshti; Sigrid Pöcher; Reza Vali; Peter Waldenberger; Gabriele Broinger; Michael Nader; Susanne Kohlfürst; Christian Pirich; Henning Dralle; Werner Langsteger
Journal:  Eur Radiol       Date:  2009-01-21       Impact factor: 5.315

Review 5.  Role of surgeons in clinical trials for thyroid cancer.

Authors:  Y Nancy You; Samuel A Wells
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

6.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Authors:  Bruce G Robinson; Luis Paz-Ares; Annetta Krebs; James Vasselli; Robert Haddad
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

7.  Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.

Authors:  Jennifer M J Schreinemakers; Menno R Vriens; Gerlof D Valk; Jan-Willem B de Groot; John T Plukker; Klaas M A Bax; Jaap F Hamming; Rob B van der Luijt; Daniel C Aronson; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

8.  The dichloromethane fraction of Stemona tuberosa Lour inhibits tumor cell growth and induces apoptosis of human medullary thyroid carcinoma cells.

Authors:  Zengxia Li; Sonja Sturm; Hermann Stuppner; Elisabeth Schraml; Victor Aguiriano Moser; Veronika Siegl; Roswitha Pfragner
Journal:  Biologics       Date:  2007-12

Review 9.  Vandetanib: in medullary thyroid cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 10.  Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Authors:  Cosimo Durante; Alessandra Paciaroni; Katia Plasmati; Fabiana Trulli; Sebastiano Filetti
Journal:  Endocrine       Date:  2013-04-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.